EDITORIAL

Cartilage Repair in 2025: Hope, Hype, or Horizon?

Mostafa Shahrezaee, MD [1]; Reza Heidari, PhD [2]

[1] Trauma and Surgery Research Center, AJA University of Medical Sciences, Tehran, Iran

[2] Medical Biotechnology Research Center, AJA University of Medical Sciences, Tehran, Iran

Overview of Current Cartilage Repair Modalities

C Cartilage injury and degeneration are among the most prevalent musculoskeletal disorders, affecting more than 500 million people worldwide.[1] Autograft transplantation provides an effective treatment for focal cartilage defects, particularly in younger patients; however, its use is limited by donor-site morbidity, restricted graft availability, and biomechanical mismatch.[2,3] Conventional approaches to cartilage repair include autologous chondrocyte implantation (ACI), bone marrow stimulation or microfracture, stem cell transplantation, and artificial cartilage or biomaterial implants.[4] Although ACI is considered a major milestone, it frequently results in fibrocartilage with inferior biomechanical properties compared to native tissue. Stem cell–based therapies hold promise due to their multipotency and paracrine effects, yet challenges persist regarding cell engraftment, immunogenicity, and potential tumorigenicity.[5,6] Microfracture techniques stimulate endogenous repair by creating access channels to the bone marrow; however, they also predominantly generate fibrocartilage, which deteriorates over time.4 These limitations have accelerated the shift toward biologically driven, patient-specific regenerative strategies.

Innovations and Technologies in 2025

The landscape of cartilage regenerative medicine has advanced rapidly with the emergence of innovative technologies. Three-dimensional (3D) bioprinting enables the in situ fabrication of patient-specific constructs with precisely organized cellular and extracellular matrix components.[7,8] Extracellular vesicles (EVs), particularly exosomes, have attracted significant attention as cell-free therapeutics capable of modulating inflammation, enhancing chondrocyte proliferation, and promoting matrix synthesis.[9] Recent bioengineering strategies have further refined EV targeting, cargo loading, and functional performance, thereby increasing their therapeutic potential. Moreover, genetic engineering tools such as CRISPR are being investigated to upregulate chondrogenic pathways, while advanced hydrogels and smart biomaterials provide enhanced mechanical support and controlled delivery of bioactive molecules.

Hope

Early clinical evidence indicates that advanced therapies, including engineered exosomes, 3D-bioprinted scaffolds, and combination approaches, may alleviate pain, improve joint function, and promote more effective tissue regeneration—while minimizing the risks of immune rejection and tumorigenicity associated with stem cell transplantation.[10] Advances in high-throughput omics technologies and targeted drug delivery are enabling more precise, patient-tailored interventions, offering the potential for improved clinical outcomes through personalized therapeutics.[11,12]

Hype

Despite encouraging progress, much of the current enthusiasm remains speculative. Many emerging strategies are still confined to preclinical or early-phase clinical trials. Existing studies frequently involve small sample sizes and short follow-up durations, making it difficult to draw definitive conclusions regarding long-term safety and efficacy.[13] Furthermore, high production costs, the absence of universally accepted manufacturing standards, regulatory uncertainty, and an incomplete understanding of underlying biological mechanisms continue to hinder large-scale clinical translation. Consequently, inflated expectations in both academic and commercial arenas may overshadow the need for rigorous validation and increase the risk of premature clinical adoption.

Horizon

Looking ahead, the convergence of bioengineering, systems biology, and omics-based precision medicine approaches is poised to transform cartilage repair.[14] Combinatorial strategies—integrating cell-derived exosomes, bioactive scaffolds, gene therapies, and smart nanomedicine—are

Corresponding Author: Mostafa Shahrezaee, Trauma and Surgery Research Center, AJA University of Medical Sciences, Tehran, Iran

Email: moshahrezaye@yahoo.com

THE ONLINE VERSION OF THIS ARTICLE
ABJS.MUMS.AC.IR

Arch Bone Jt Surg. 532-534 Doi: 10.22038/abjs.2025.90121.4089 http://abjs.mums.ac.ir

being developed to tackle the multifaceted challenges of cartilage regeneration. Expanding the scale and rigor of clinical trials will be essential for defining best practices, establishing standardized protocols, and ensuring long-term safety. Ultimately, the field is moving toward fully integrated, minimally invasive, and patient-specific regenerative solutions; however, achieving these goals will require both scientific rigor and regulatory clarity.

Conclusion

In 2025, the field of cartilage repair stands at the intersection of promising breakthroughs, inflated expectations, and a future rapidly shaped by technological innovation. While engineered exosomes, bioprinting, and combination therapeutics hold the potential to redefine clinical outcomes, substantial barriers remain before these approaches can be established as standard of care. Sustained research efforts, rigorous clinical validation, and careful translation from laboratory to bedside will be essential for advancing from symptomatic management to true cartilage regeneration for patients worldwide.

Acknowledgement

N/A

Authors Contribution: Authors who conceived and designed the analysis: Mostafa Shahrezaee, Reza Heidari/Authors who collected the data: Reza Heidari/Authors who contributed data or analysis tools: Mostafa Shahrezaee/Authors who performed the analysis: Mostafa Shahrezaee, Reza Heidari/Authors who wrote the paper: Mostafa Shahrezaee, Reza Heidari

Declaration of Conflict of Interest: The authors do NOT have any potential conflicts of interest for this manuscript.

Declaration of Funding: The authors received NO financial support for the preparation, research, authorship, and publication of this manuscript.

Declaration of Ethical Approval for Study: This study was exempt from ethical approval as it did not involve human participants, animal subjects, or identifiable personal data.

Declaration of Informed Consent: There is no information (such as names, initials, hospital identification numbers, or photographs) in the submitted manuscript that can be used to identify patients. Therefore, informed consent was not required.

Mostafa Shahrezaee MD [1]
Reza Heidari PhD [2]

1 Trauma and Surgery Research Center, AJA University of Medical Sciences, Tehran, Iran

2 Medical Biotechnology Research Center, AJA University of Medical Sciences, Tehran, Iran

References

1. Li HZ, Liang XZ, Sun YQ, Jia HF, Li JC, Li G. Global, regional, and national burdens of osteoarthritis from 1990 to 2021: findings from the 2021 global burden of disease study. Front Med (Lausanne).2024:11:1476853. doi: 10.3389/fmed.2024.147685.
2. Ghadamzadeh M, Mohsenzadeh SA, Bagheri SM, et al. MRI Findings after Injection of Single and Double Centrifuged Platelet-Rich Plasma and Placebo (Normal Saline) in Patients with Knee Osteoarthritis: A Randomized Double-Blind Clinical Trial with Six-Month Follow-Up. Arch Bone Jt Surg. 2025:-. doi:10.22038/abjs.2025.80109.3658
3. RODRIGUEZ-MERCHAN EC, De la Corte-Rodriguez H. The Role of Intraarticular Injections of Hyaluronic Acid and Platelet Rich Plasma for the Treatment of Articular Pain in Knee Osteoarthritis. Arch Bone Jt Surg. 2025;13(1):54-61. doi:10.22038/abjs.2024.78852.3621
4. Karami P, Laurent A, Philippe V, Applegate LA, Pioletti DP, Martin R. Cartilage Repair: Promise of Adhesive Orthopedic Hydrogels. Int J Mol Sci. 2024;25(18):9984. doi: 10.3390/ijms25189984.
5. Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al. Effects of Combined Intrathecal Mesenchymal Stem Cells and Schwann Cells Transplantation on Neuropathic Pain in Complete Spinal Cord Injury: A Phase II Randomized Active-Controlled Trial. Cell Transplant. 2025:34:9636897241298128. doi: 10.1177/09636897241298128.
6. Akbariqomi M, Heidari R, Gargari SS, et al. Evaluation and statistical optimization of a method for methylated cell-free fetal DNA extraction from maternal plasma. *J Assist Reprod Genet*. May 2019;36(5):1029-1038. doi:10.1007/s10815-019-01425-w
7. Longfei H, Wenyuan H, Weihua F, et al. Exosomes in cartilage microenvironment regulation and cartilage repair. Front Cell Dev Biol. 2025:13:1460416. doi: 10.3389/fcell.2025.1460416.
8. Jahani A, Nourbakhsh MS, Ebrahimzadeh MH, Mohammadi M, Yari D, Moradi A. Biomolecules-loading of 3D-printed alginate-based scaffolds for cartilage tissue engineering applications: a review on current status and future prospective. Arch Bone Jt Surg. 2024;12(2):92-101. doi: 10.22038/ABJS.2023.73275.3396.
9. Di Bella MA. Overview and Update on Extracellular Vesicles: Considerations on Exosomes and Their Application in Modern Medicine. Biology (Basel). 2022;11(6):804. doi: 10.3390/biology11060804.
10. Chen Z, Zhou T, Luo H, et al. HWJMSC-EVs promote cartilage regeneration and repair via the ITGB1/TGF-β/Smad2/3 axis mediated by microfractures. J Nanobiotechnology. 2024;22(1):177. doi: 10.1186/s12951-024-02451-2.

11. Wu X, Tao W, Lan Z, et al. pH-Responsive Engineered Exosomes Enhance Endogenous Hyaluronan Production by Reprogramming Chondrocytes for Cartilage Repair. Adv Healthc Mater. 2025;14(10):e2405126. doi: 10.1002/adhm.202405126.
12. Liao H-J, Yang Y-P, Liu Y-H, et al. Harnessing the potential of mesenchymal stem cells–derived exosomes in degenerative diseases. Regen Ther. 2024:26:599-610. doi: 10.1016/j.reth.2024.08.001.
13. Tandon R, Srivastava N. Unravelling exosome paradigm: Therapeutic, diagnostic and theranostics application and regulatory consideration. Life Sci. 2025:366-367:123472. doi: 10.1016/j.lfs.2025.123472.
14. Mamachan M, Sharun K, Banu SA, et al. Mesenchymal stem cells for cartilage regeneration: Insights into molecular mechanism and therapeutic strategies. Tissue Cell. 2024:88:102380. doi: 10.1016/j.tice.2024.102380.